Biopharma
ByAtrium Therapeutics Spins Out with $270M Cash from Avidity—Preclinical AOCs Target Rare Genetic Cardiomyopathies
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following Novartis’ $12 billion…
Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…
BioMarin’s Roctavian Withdrawal—$240M Q4 Charge, <200 U.S. Patients Served Amid Gene Therapy Market Reality Check
Published by BioNextAI Media – BioMarin Pharmaceutical Inc. voluntarily withdrew its pioneering hemophilia A gene therapy ROCTAVIAN (valoctocogene roxaparvovec-rvox)…
Boehringer’s Hernexeos Secures Record 44-Day FDA Nod via Priority Voucher—76% ORR in HER2-Mutant NSCLC Frontier
Published by BioNextAI Media – Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets) snagged ultra-fast FDA accelerated approval in just 44 days…
The $10B+ Pharma Titans of 2025: Fortress Builders or House of Cards?
In 2025, only nine pharmaceutical brands crossed the $10 billion revenue threshold, collectively generating $125B+ while representing 25% of global pharma sales—yet their…
How Does Eli Lilly Secure $100B+ Obesity Dominance Through 8 Triple/Triple+ Agonist Launches by 2030?
Eli Lilly establishes unrivaled obesity leadership through its 40 Phase 2/3 programs and 34 discovery-stage assets, commanding 60% US GLP-1 market share via Mounjaro/Zepbound ($39.5B 2025 revenue)…
